ScreenerHero

ZYME Zymeworks Inc.

Partial data
NYSE · US · Healthcare · Biotechnology · zymeworks.com
25.89USD-3.43%Mkt Cap: 1.92B $P/E: —

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjug…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.92B USD
Enterprise Value1.59B USD
Revenue (TTM)37.13M USD
Gross Profit-91.58M USD
Net Income (TTM)-81.13M USD
Revenue/Share0.50 USD
Last Price25.89 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees231
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS98985Y1082
Valuation
P/E (Trailing)—
P/E (Forward)28.16
PEG—
EV/EBITDA-10.54
EV/Revenue42.76
P/S50.17
P/B23.08
EPS (TTM)-1.98
EPS (Forward)0.92
52W Range
15.8165% of range31.34
52W High31.34 USD
52W Low15.81 USD
Profitability
Gross Margin-246.66%
Oper. Margin-918.95%
EBITDA Margin0.00%
Profit Margin-76.56%
ROE-30.22%
ROA-23.41%
Growth
Revenue Growth-90.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-33.01M USD
CapEx (TTM)2.35M USD
FCF Margin-175.24%
FCF Yield-3.39%
Net Debt-254.69M USD
Net Debt/EBITDA1.69
Balance Sheet
Debt/Equity0.07
Current Ratio6.32
Quick Ratio5.86
Book Value/Sh1.13 USD
Cash/Share3.81 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)41.07 USD
Upside (mean)+58.6%
Target Range32.00 USD – 60.00 USD
32.00+58.6% to mean60.00
# Analysts14
Ownership
Shares Out.71.20M
Float65.84M
Insiders1.31%
Institutions98.97%
Short Interest
Short Ratio6.7d
Short % Float10.47%
Short % Out.6.91%
Shares Short4.94M
Short (prev mo.)4.54M
Technical
SMA 5026.07 (-0.7%)
SMA 20025.10 (+3.1%)
Beta1.19
S&P 52W Chg13.94%
Avg Vol (30d)677.22K
Avg Vol (10d)955.66K
Technical Indicators
RSI (14)49.2
MACD0.1189
MACD Signal0.4487
MACD Hist.-0.3299
BB Upper30.94 USD
BB Middle28.00 USD
BB Lower25.06 USD
BB Width20.99%
ATR (14)1.216 USD
Vol Ratio (20d)0.71x